FOUNDAYO

all catalysts(0)

nothing on the calendar yet

News(10)

• Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
  Eli Lilly’s weight loss pill Foundayo has had a “slower-than-hoped” launch, according to BMO Capital Markets, which contended that the indirect comparison data—despite falling short of definitive p…
  biospace · 4d ago
• Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
  With sales of the oral GLP-1 medicine rising quickly, executives reassured investors that Novo has secured production capacity to support continued growth.
  biospace · 12d ago
• Novo talks up drug launches in effort to win back investors
  At a “capital markets day” in London, executives outlined a roadmap to better compete with key rival Eli Lilly and soon bring forth several multibillion-dollar products.
  biopharma_dive · 13d ago
• Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
  Novo has “gone shopping” to fill pipeline gaps, with a focus on obesity and diabetes, plus an expansion in blood and endocrine disorders, liver diseases and cardiovascular conditions.
  biospace · 13d ago
• Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
  With reports leaking out of investor discontent, CEO Mike Doustdar opened Novo's Capital Markets Day by acknowledging that the company’s leadership “have to convince” the audience that “there is a…
  fiercebiotech · 13d ago
• Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
  The multi-drug partnership with Orbis Medicines—which Novo Holdings has backed since the biotech's seed rounds—is focused on cardiometabolic targets, but the technology at the center of the deal co…
  biospace · 17d ago
• Lilly cans early experimental obesity drug after ‘high bar’ not met
  Eli Lilly has put the kibosh on an early-stage obesity drug after the candidate didn’t meet the pharma giant’s lofty expectations.
  fiercebiotech · 20d ago
• Corbus posts phase 1 obesity data for drug mechanism that defeated Novo, Sanofi
  Corbus Pharmaceuticals’ phase 1b obesity trial has generated evidence that its CB1 inverse agonist may be less prone to the neuropsychiatric side effects that affected Novo Nordisk and Sanofi. The…
  fiercebiotech · 20d ago
• No more Nordisk as Novo goes it alone amid rebranding push
  As Novo Nordisk continues its epic battle with Eli Lilly for market share in the increasingly competitive obesity and diabetes space, Novo is launching a major rebrand of its business, logo and name.
  fiercebiotech · 21d ago
• Caspian launches with $50M, Lilly support to advance disease-modifying diabetes bet
  Kura Oncology has spun out Caspian around KO-7246, which seeks to increase the number and activity of beta cells in the pancreas, in turn boosting insulin production in patients with diabetes.
  biospace · 25d ago